343 varieties have passed the preliminary review and are included in the 2022 medical insurance directory, and the four highlights are the first to see! (Attached list)

On September 17, the National Medical Insurance Bureau officially released the "List of Declared Drugs Approved by the Formal Examination of the Adjustment of the Drug Catalogue of National Basic Medical Insurance, Industrial Injury Insurance and Maternity Insurance in 2022"

On September 17, the National Medical Insurance Bureau officially released the "List of Declared Drugs Approved by the Formal Examination of the Adjustment of the Drug Catalogue of National Basic Medical Insurance, Industrial Injury Insurance and Maternity Insurance in 2022"

On September 6, the National Medical Insurance Bureau released the "List of Drugs and Related Information Approved by the Preliminary Form Review of the 2022 National Medical Insurance Drug Catalogue", and a total of 344 varieties passed the preliminary examination, including 199 Western medicines and proprietary Chinese medicines outside the list, and 145 Western medicines and proprietary Chinese medicines in the directory, with a publicity time of one week (as of 12 days).

On September 6, the National Medical Insurance Bureau released the "List of Drugs and Related Information Approved by the Preliminary Form Review of the 2022 National Medical Insurance Drug Catalogue", and a total of 344 varieties passed the preliminary examination, including 199 Western medicines and proprietary Chinese medicines outside the list, and 145 Western medicines and proprietary Chinese medicines in the directory, with a publicity time of one week (as of 12 days).

Compared with the preliminary list, Harbin Tianmei Pharmaceutical's metronidazole vaginal expansion plug is not on the

This round of medical insurance negotiations has multiple points to

Nearly 90 oncology drugs "dominate" Nearly 90 oncology drugs "dominate"

Imported PD-(L)1 collective "silence"?

Imported PD-(L)1 collective "silence"? Imported PD-(L)1 collective "silence"?

From the indications, anti-tumor and immunomodulators were selected for the largest number of preliminary examination catalogs, a total of 89

From the indications, anti-tumor and immunomodulators were selected for the largest number of preliminary examination catalogs, a total of 89

Judging from the preliminary examination list, Henlius Fuhong Sluliumab Injection, Corning Jerry's Envolimumab Injection, and Kangfang Bio's Cardonizumab Injection were shortlisted

What is surprising is that the imported PD-(L)1 products that have been running for many years, the medical insurance negotiations directly and collectively "lost their voice", whether it is Merck's pabolizumab, BMS's navurizumab, or Roche's atilizumab, AstraZeneca's dulvalizumab, all did not appear in

The enthusiasm of foreign enterprises is highThe enthusiasm of foreign enterprises is high

Novartis has the largest number of products

The largest number of Novartis products, the largest number of Novartis products

This year, 9 companies have declared more than 5 drugs, of which Novartis Pharma has participated in this year's medical insurance negotiations with 14 drugs, becoming the enterprise

This year, 9 companies have declared more than 5 drugs, of which Novartis Pharma has participated in this year's medical insurance negotiations with 14 drugs, becoming the enterprise

The second place is Pfizer, the number of medical insurance negotiations this year is 11, of which pipexicil capsules, injectable acetate diagaric acid also appeared on the preliminary examination list

Sanofi (Beijing), AstraZeneca (Wuxi) and Chia Tai Tianqing declared 7 drugs; Bayer declared 6 drugs; Jiangsu Haosen and BeiGene Shenzhou (Beijing) declared the number of drugs for 5

"Sky-high" CAR-T products have attracted attention to "sky-high" CAR-T products and then attracted attention

Chinese medicine enterprises actively become the "big year"

Chinese medicine enterprises actively become "big year" Chinese medicine enterprises actively become "big year"

WuXi Juno brought a second domestic CAR-T product, Ricky Orense Injection (Cignatal), which was approved for marketing in September 2021 and entered the medical insurance negotiation catalogue

WuXi Juno brought a second domestic CAR-T product, Ricky Orense Injection (Cignatal), which was approved for marketing in September 2021 and entered the medical insurance negotiation catalogue

Ricky Orance injection 1.
29 million / needle purchase hanging net price, than Fosun Kate's 1.
2 million / needle Achillense injection is more expensive 90,000 yuan, with Fosun Kate's previous experience, WuXi Juno product pricing is still actively declaring medical insurance negotiations, is it to attract traffic, or really have the confidence to press down the product price and face the medical insurance negotiation "soul bargaining"? "How much to fall" has also become the focus of public attention

In this preliminary review catalogue, it is worth noting in the field of proprietary Chinese medicine that companies such as Tianjin Tasly and Jilin Huakang have brought pediatric drugs
such as peony antispasmodic granules and unclogging granules.
While promoting the development of traditional Chinese medicine products, it also enriches the choice
of pediatric drugs.
It breaks the previous limitation
that pediatric drugs in the medical insurance directory are only Western drugs.

In this preliminary review catalogue, it is worth noting in the field of proprietary Chinese medicine that companies such as Tianjin Tasly and Jilin Huakang have brought pediatric drugs
such as peony antispasmodic granules and unclogging granules.
While promoting the development of traditional Chinese medicine products, it also enriches the choice
of pediatric drugs.
It breaks the previous limitation
that pediatric drugs in the medical insurance directory are only Western drugs.
04

Rare diseases are attracting renewed attention

Rare diseases re-attract attention to rare diseases and re-attract attention

Sanofi accelerates across the board

Sanofi full acceleration Sanofi full acceleration

In this year's preliminary catalogue, on the basis of continuing to support innovative drugs, the focus on drugs for the treatment of rare diseases is also highlighted
.
According to statistics, there are nearly 20 drugs
in the field of rare diseases and rare diseases in the preliminary review list.

In this year's preliminary catalogue, on the basis of continuing to support innovative drugs, the focus on drugs for the treatment of rare diseases is also highlighted
.
According to statistics, there are nearly 20 drugs
in the field of rare diseases and rare diseases in the preliminary review list.

Among them, Sanofi products have the largest number of products, and 4 products have been shortlisted for the preliminary examination catalog, including arasidase for injection for the treatment of Pompeii disease α, agarase β for injection of Fabre disease, laronidase concentration solution for injection of mucopolysaccharide storage disease, and imidase for injection of Gosher disease
.

Among them, Sanofi products have the largest number of products, and 4 products have been shortlisted for the preliminary examination catalog, including arasidase for injection for the treatment of Pompeii disease α, agarase β for injection of Fabre disease, laronidase concentration solution for injection of mucopolysaccharide storage disease, and imidase for injection of Gosher disease
.

Local companies have also begun to "soar" in the field of rare diseases! Nuoai Pharmaceutical for the treatment of mucopolysaccharide storage disease type II Aido sulfate ß injection, Guangzhou Zhaoke Lianfa Pharmaceutical research and development of muscular atrophy lateral sclerosis of riluzole oral suspension, Hanguang Pharmaceutical for tyrosinemia type I nitisinon capsules, Zhaoke Pharmaceutical for urea circulation disorder of sodium phenbutyrate granules, Wanbond Pharmaceutical for the treatment of myasthenia gravis Huperzine A injection, Hengbang Pharmaceutical for the treatment of optic nerve myelitis inertimab injection, etc
.

Local companies have also begun to "soar" in the field of rare diseases! Nuoai Pharmaceutical for the treatment of mucopolysaccharide storage disease type II Aido sulfate ß injection, Guangzhou Zhaoke Lianfa Pharmaceutical research and development of muscular atrophy lateral sclerosis of riluzole oral suspension, Hanguang Pharmaceutical for tyrosinemia type I nitisinon capsules, Zhaoke Pharmaceutical for urea circulation disorder of sodium phenbutyrate granules, Wanbond Pharmaceutical for the treatment of myasthenia gravis Huperzine A injection, Hengbang Pharmaceutical for the treatment of optic nerve myelitis inertimab injection, etc
.

In the next step, the National Medical Insurance Bureau will organize expert review and other work in accordance with the requirements of the Interim Measures for the Administration of Drugs in Basic Medical Insurance and the Work Plan for the Adjustment of the Drug Catalogue of National Basic Medical Insurance, Industrial Injury Insurance and Maternity Insurance in 2022
.
Relevant enterprises are invited to pay attention to the national medical insurance service platform "2022 National Medical Insurance Drug Catalogue Adjustment Declaration Module" to obtain relevant review, negotiation, agreement and other information
of the National Medical Insurance Bureau in a timely manner.

In the next step, the National Medical Insurance Bureau will organize expert review and other work in accordance with the requirements of the Interim Measures for the Administration of Drugs in Basic Medical Insurance and the Work Plan for the Adjustment of the Drug Catalogue of National Basic Medical Insurance, Industrial Injury Insurance and Maternity Insurance in 2022
.
Relevant enterprises are invited to pay attention to the national medical insurance service platform "2022 National Medical Insurance Drug Catalogue Adjustment Declaration Module" to obtain relevant review, negotiation, agreement and other information
of the National Medical Insurance Bureau in a timely manner.